Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma

Br J Dermatol. 2018 Jan;178(1):302-303. doi: 10.1111/bjd.15970. Epub 2018 Jan 10.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Brentuximab Vedotin
  • Humans
  • Immunoconjugates*
  • Ki-1 Antigen*
  • Lymphoma, T-Cell, Cutaneous

Substances

  • Immunoconjugates
  • Ki-1 Antigen
  • Brentuximab Vedotin